Brugada syndrome clinical update
- Resource Type
- Authors
- Sei Iwai; Ethan Gregory Hoch; Risheek Kaul; Daniel Frenkel; Jason T. Jacobson; Wilbert S. Aronow; Rhadames Rojas
- Source
- Hospital Practice. 49:255-261
- Subject
- medicine.medical_specialty
030204 cardiovascular system & hematology
Ventricular tachycardia
Sudden cardiac death
Diagnosis, Differential
Electrocardiography
03 medical and health sciences
0302 clinical medicine
Asian People
Risk Factors
Internal medicine
medicine
Humans
ST segment
cardiovascular diseases
030212 general & internal medicine
Brugada Syndrome
Brugada syndrome
Fibrillation
medicine.diagnostic_test
business.industry
fungi
General Medicine
medicine.disease
Defibrillators, Implantable
Blockade
Death, Sudden, Cardiac
Catheter Ablation
Etiology
Cardiology
medicine.symptom
business
Anti-Arrhythmia Agents
- Language
- ISSN
- 2377-1003
2154-8331
Brugada syndrome (BrS) was initially described in southeast Asians with a structurally normal heart presenting with polymorphic ventricular tachycardia and fibrillation. This condition is marked by J-point elevation ≥ 2 mm with coved-type ST segment elevation followed by negative T wave inversions in at least one precordial lead (V1 or V2) when other etiologies have been excluded. These changes on electrocardiogram (EKG) can either be spontaneous or manifest after sodium channel blockade. The worldwide prevalence of BrS is about 0.4%; however, it is higher in the Asian population at 0.9%. This article will review the current hypotheses regarding the pathophysiology, spectrum of clinical presentation, strategies for prevention of sudden cardiac death and the treatment for recurrent arrhythmias in BrS.